MedTrace Logo

MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study

NCT07312136 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2025-12-31

No results posted yet for this study

Summary

The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.

Conditions

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Cirrhosis
  • Advanced Fibrosis
  • Sarcopenia
  • Obesity & Overweight
  • Type 2 Diabetes
  • Hypertension
  • OSAS (Obstructive Sleep Apneas Syndrome)
  • Metabolic Syndrome

Sponsors & Collaborators

  • University Hospital, Linkoeping

    collaborator OTHER

  • Amra Medical AB

    collaborator INDUSTRY

  • Linkoeping University

    lead OTHER_GOV

Principal Investigators

  • Patrik Nasr, M.D., Ph.D. · Department of Health, Medicine and Caring Sciences, Linköping University, and Department of Gastroenterology and Hepatology, Linköping University Hospital, Linköping, Sweden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-16
Primary Completion
2031-12-31
Completion
2034-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07312136 on ClinicalTrials.gov